Last updated: September 6, 2026
Succimer is a mature oral chelating agent used primarily for lead poisoning. The U.S. market is small, prescription-driven, and shaped more by public-health events, government procurement, pediatric screening, and manufacturing continuity than by routine commercial demand. The original brand, Chemet, no longer provides a meaningful exclusivity platform. Generic succimer is available, but limited supplier participation and episodic demand can produce pricing volatility.
What is succimer used for and how large is the addressable market?
Succimer, also known as dimercaptosuccinic acid or DMSA, is an oral chelator indicated for the treatment of lead poisoning in pediatric patients with blood lead concentrations above 45 micrograms per deciliter. The usual regimen is 10 mg/kg every eight hours for five days, followed by 10 mg/kg every 12 hours for 14 days, with a maximum single dose of 500 mg.[1]
| Attribute |
Succimer |
| Active ingredient |
Dimercaptosuccinic acid |
| Primary indication |
Pediatric lead poisoning |
| U.S. brand |
Chemet |
| Dosage form |
100 mg capsules |
| FDA approval |
1991 |
| Administration |
Oral |
| Therapeutic class |
Heavy-metal chelator |
| Primary alternatives |
Calcium disodium edetate, dimercaprol |
| U.S. market structure |
Generic-dominated, low-volume, concentrated |
Succimer addresses a narrow clinical population. Most children with elevated blood lead levels do not require chelation. Chelation is generally reserved for substantially elevated concentrations, severe symptoms, or clinical situations requiring specialist management. CDC surveillance has shown a long-term decline in childhood blood lead exposure, reducing the routine treatment pool even as screening continues in high-risk communities.[2]
The addressable market is therefore constrained by:
- Declining average childhood blood lead levels.
- Reduced use of lead-containing consumer products and gasoline.
- Localized exposure events involving contaminated housing, water, soil, or industrial activity.
- Pediatric treatment protocols that reserve chelation for high blood lead concentrations.
- Competition from injectable chelators in severe or hospitalized cases.
The market can expand temporarily after a contamination event, but those increases usually do not create durable baseline demand.
What is the U.S. FDA and Orange Book status of succimer?
Chemet was approved under FDA NDA 019998. Succimer is no longer protected by new chemical entity exclusivity, and the commercial market is supplied through generic abbreviated new drug applications.
The FDA-approved product is a prescription drug. There is no biosimilar pathway because succimer is a chemically synthesized small molecule rather than a biologic.
| Regulatory issue |
Status |
| FDA approval |
Approved |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
No current commercial relevance |
| Generic pathway |
ANDA |
| Biosimilar risk |
Not applicable |
| Orange Book patent barrier |
No material active barrier identified for current generic entry |
| Prescription status |
Prescription-only |
| Primary regulatory risk |
Product quality, supply continuity, and manufacturing compliance |
The original brand approval established the clinical and regulatory framework, but the commercial rights associated with the brand do not prevent generic substitution. FDA Orange Book records for Chemet do not identify a current patent estate that would support a meaningful delay to generic competition.[3]
When does succimer lose exclusivity?
Succimer lost practical exclusivity years ago. The original approval occurred in 1991, placing the product well beyond the five-year NCE exclusivity period and any potential pediatric exclusivity associated with the initial approval.
No active commercial exclusivity is expected to support a branded price premium. Any current market protection would have to arise from manufacturing capability, supply reliability, customer contracts, regulatory complexity, or temporary competitor exits rather than from patent rights.
Succimer exclusivity timeline
| Milestone |
Timing |
| Original FDA approval of Chemet |
1991 |
| NCE exclusivity expiration |
Mid-1990s |
| Generic availability |
Established before the current market period |
| Current market position |
Generic-dominated |
| Expected patent-driven launch barrier |
None material |
Succimer is also not a candidate for a conventional reformulation strategy with strong market protection unless a company develops a new dosage form, delivery system, or combination product that receives separate FDA approval. Such a product would need to demonstrate meaningful clinical or practical value in a small patient population.
How many patents cover succimer?
The original active ingredient is an old chelating compound, and the core composition-of-matter protection has expired. No meaningful patent estate appears to cover the commercially relevant 100 mg oral capsule market.
| Patent category |
Commercial relevance |
| Composition of matter |
Expired |
| Basic oral capsule formulation |
No meaningful current barrier |
| Method of treating lead poisoning |
Any historical protection is expired or commercially weak |
| Manufacturing process |
Possible process know-how, but not a broad market exclusion |
| Pediatric dosing |
Established labeling, not a current exclusivity platform |
| New delivery technology |
No widely commercialized protected platform identified |
Manufacturing know-how may still matter. A supplier must consistently produce succimer to required purity specifications, control impurities associated with sulfur-containing compounds, validate capsule filling, and maintain FDA-compliant facilities. Those capabilities can deter entry even when patents do not.
The distinction is important for investors. Succimer has low legal exclusivity but can have moderate operational barriers if only a few manufacturers maintain validated production and regulatory files.
Which companies compete in the succimer market?
The market includes the historical Chemet brand and generic succimer suppliers. The exact supplier set can change as manufacturers enter or withdraw from the market, and product availability can vary by wholesaler and pharmacy channel.
Competition is based on:
- FDA-approved product availability.
- Wholesale acquisition price.
- Medicaid and public-payer reimbursement.
- Capacity to support emergency orders.
- Supply-chain reliability.
- Hospital and poison-control-center purchasing relationships.
- Ability to maintain inventory despite low routine demand.
Brand competition is limited. Generic competition is more relevant, but the market is not equivalent to a high-volume primary-care generic. A supplier may have regulatory approval yet maintain little commercial inventory because demand is intermittent.
How does succimer compare with competing chelators?
| Product |
Route |
Typical market role |
Commercial distinction |
| Succimer |
Oral |
Moderate pediatric lead poisoning |
Easier outpatient administration |
| Calcium disodium edetate |
Intravenous or intramuscular |
Severe lead poisoning or inpatient treatment |
More intensive administration |
| Dimercaprol |
Intramuscular |
Severe poisoning, often with other chelators |
Administration burden and adverse-effect profile |
| Penicillamine |
Oral |
Limited alternative use |
Less central to acute lead treatment |
Succimer’s oral route is its main competitive advantage. It avoids infusion infrastructure and reduces the burden of outpatient treatment. That advantage supports continued clinical use even without patent protection.
What formulation patents protect succimer?
The marketed U.S. dosage form is a 100 mg capsule. No widely recognized active formulation patent currently protects the standard succimer capsule.
Potential formulation opportunities include:
- Pediatric liquid formulations.
- Smaller-dose capsules or tablets.
- Taste-masked oral suspensions.
- Unit-dose emergency packaging.
- Heat-stable stockpiling formats.
- Combination packaging with blood lead testing or treatment instructions.
These opportunities have limited commercial value unless they solve a specific clinical or procurement problem. A liquid formulation could improve administration for young children, but it would require stability, palatability, preservative, dosing accuracy, and abuse-prevention work. In a small market, the development cost may be difficult to recover through ordinary retail sales.
Are there Paragraph IV challenges or succimer patent lawsuits?
Succimer does not present a material current Paragraph IV litigation story. The relevant product is already genericized, and the historical patent landscape does not create a significant active barrier for ANDA applicants.
| Legal issue |
Current commercial assessment |
| Paragraph IV challenge |
No major current dispute identified |
| Patent infringement litigation |
No material active litigation affecting generic launch identified |
| Settlement agreement |
No commercially significant patent settlement identified |
| Formulation litigation |
No major dispute affecting the standard capsule market |
| Regulatory exclusivity litigation |
No active exclusivity issue identified |
The principal legal risks are more likely to involve product liability, manufacturing compliance, supply contracts, or alleged quality failures than patent enforcement.
What is the financial trajectory for succimer?
Succimer’s financial trajectory is best understood as a low-volume, high-variability generic market rather than a conventional growth pharmaceutical.
Historical phase: branded specialty product
The early commercial period was based on Chemet as a specialized pediatric antidote. Revenue was limited by the narrow indication, but the product had clinical differentiation because it offered oral treatment for lead poisoning.
Generic transition
After loss of exclusivity, generic entry reduced the ability to sustain brand pricing. Revenue shifted from branded franchise economics to manufacturing and distribution economics. The product became dependent on prescription volume, public-sector demand, and availability at wholesalers.
Current mature-market phase
The current market has four financial characteristics:
- Low baseline prescription volume.
- Irregular demand spikes.
- Limited opportunity for large-scale volume growth.
- Potential pricing volatility when one or more suppliers withdraw.
Public company filings generally do not report succimer as a standalone revenue line. Financial exposure must therefore be estimated through portfolio-level disclosures, product listings, market-share data, reimbursement records, and procurement activity rather than through reported product sales.
Revenue sensitivity
| Driver |
Effect on succimer revenue |
| Childhood lead exposure trends |
Long-term negative pressure |
| Contamination events |
Short-term positive spikes |
| Government stockpiling |
Can increase order size and inventory requirements |
| Supplier exits |
Can increase price but reduce market stability |
| New generic entrants |
Usually lowers price |
| Pediatric screening expansion |
Supports diagnosis but not necessarily chelation volume |
| Formulation innovation |
Could expand use, but requires new clinical and regulatory investment |
A supplier can generate attractive gross margins during a constrained-supply period, but that outcome is not equivalent to durable market expansion. High realized prices can attract new entrants, trigger payer scrutiny, or lead to inventory normalization.
What generic entry risks exist for succimer?
Generic launch risk is low from a patent perspective and moderate from an operational perspective.
Low patent risk
There is no meaningful active composition patent expected to block an ANDA applicant. A prospective supplier would not face the type of multi-year patent litigation common in blockbuster medicines.
Moderate regulatory and manufacturing risk
The main barriers are:
- Demonstrating bioequivalence.
- Maintaining consistent assay and impurity profiles.
- Producing a stable capsule at commercial scale.
- Establishing a compliant supply chain for active pharmaceutical ingredient.
- Maintaining a validated manufacturing site.
- Supporting FDA inspections and postmarket obligations.
High commercial concentration risk
A new entrant may find the market unattractive because expected annual volume is small and uncertain. Hospitals, public agencies, and wholesalers may prefer incumbent suppliers with a demonstrated ability to fulfill emergency orders. That preference can limit the practical benefit of FDA approval.
How does geographic coverage affect the succimer market?
The United States is the most important regulated market for the product because of established pediatric lead screening and a defined FDA indication. International markets vary significantly in exposure patterns, regulatory status, procurement systems, and use of alternative chelators.
Demand is geographically concentrated in areas with:
- Older housing stock.
- Industrial contamination.
- Lead-related occupational exposure.
- Informal recycling or battery-processing activity.
- Contaminated water or soil.
- Higher pediatric screening rates.
Commercial demand may be strongest in regions where public health agencies maintain emergency inventories. That creates a procurement market separate from routine retail prescriptions.
International expansion would require country-specific registration, local pharmacovigilance, distribution arrangements, and reimbursement access. The small global revenue opportunity limits the attractiveness of broad geographic expansion unless the product is bundled with a broader toxicology portfolio.
What licensing deals affect succimer?
No major current licensing transaction is central to the succimer market. The product’s commercial value is generally too limited to support a large standalone royalty transaction.
Potential transaction structures would more likely involve:
- Acquisition of a generic portfolio.
- Transfer of an ANDA and manufacturing rights.
- Contract manufacturing.
- Government supply agreements.
- Regional distribution rights.
- Emergency stockpiling contracts.
A licensing deal involving succimer alone would likely be commercially modest. Its value would increase if combined with other antidotes, poison-control products, or hospital emergency medicines.
How strong is the succimer patent estate?
The patent estate is weak, but the product can retain operational value.
| Asset category |
Strength |
| Core composition patent |
None of current commercial significance |
| Standard capsule protection |
Weak |
| Method-of-use protection |
Weak or expired |
| Regulatory exclusivity |
Expired |
| Manufacturing know-how |
Moderate for qualified suppliers |
| Distribution relationships |
Moderate in emergency procurement |
| Brand recognition |
Limited, with Chemet retaining historical recognition |
| Supply scarcity value |
Potentially high during disruptions |
For an acquirer, succimer would not be a patent-led asset. Its value would depend on supply reliability, approved manufacturing capacity, procurement contracts, and the ability to manage a low-volume product profitably.
What generic launch scenarios are most likely?
Base case
Existing generic suppliers remain active, demand stays low and irregular, and pricing remains relatively stable except during temporary shortages. Revenue declines gradually with the long-term reduction in severe pediatric lead poisoning.
Upside case
A contamination event, public-health procurement program, or supplier disruption increases orders. Revenue and margins rise temporarily, especially for a company holding inventory and validated production capacity.
Downside case
Multiple suppliers compete for limited volume, reimbursement pressure increases, or a manufacturer exits after failing to achieve adequate scale. Per-unit margins fall, and the product becomes commercially unattractive despite continuing clinical need.
Product-development case
A company introduces a pediatric liquid or unit-dose formulation. The product could command a premium if it improves administration or emergency readiness, but the addressable population remains small and the commercial return depends on institutional purchasing.
What is the investment and commercial outlook for succimer?
Succimer is a defensive, niche generic rather than a growth asset. Its value lies in clinical necessity, oral administration, and the possibility of supply scarcity. Its limits are the shrinking routine treatment population, lack of patent protection, low prescription volume, and dependence on episodic public-health demand.
The strongest commercial position belongs to a manufacturer that can:
- Maintain uninterrupted FDA-compliant supply.
- Hold inventory for emergency orders.
- Serve hospital, government, and wholesale channels.
- Control API and finished-dose manufacturing costs.
- Add succimer to a broader antidote or hospital-generic portfolio.
A standalone succimer investment is unlikely to support significant revenue growth without a new formulation, procurement contract, or supply disruption. The product can still provide strategic value as part of a broader emergency-medicine portfolio.
Key Takeaways
- Succimer is an FDA-approved oral chelator for pediatric lead poisoning.
- Chemet’s original exclusivity has expired, and the market is generic-dominated.
- No material active patent barrier is expected to delay generic competition.
- The market is small, with demand driven by severe cases, public-health events, and emergency procurement.
- Oral administration remains succimer’s main clinical advantage over injectable chelators.
- Revenue is likely to remain low and volatile rather than follow a conventional growth trajectory.
- Manufacturing reliability, inventory, and government supply relationships are more important than patent ownership.
- Biosimilar competition is irrelevant because succimer is a small-molecule drug.
- Formulation innovation could create limited premium pricing, but the total addressable market would remain narrow.
- The best commercial strategy is portfolio integration with antidotes, hospital generics, or public-health supply contracts.
FAQs
Is succimer still commercially available in the United States?
Yes. Succimer is available as an FDA-approved generic product, although availability can vary by supplier, wholesaler, and pharmacy inventory.
Is Chemet still a major branded product?
No. Chemet is the historical brand associated with succimer, but current commercial activity is primarily generic and the brand does not provide a meaningful current exclusivity platform.
Can a company obtain a new patent on succimer?
A new patent could potentially cover a novel formulation, manufacturing process, or delivery system if it meets patentability requirements. A new patent would not restore protection to the old active ingredient itself.
Does succimer have orphan-drug market protection?
Succimer does not have a current orphan-drug exclusivity position that materially restricts generic competition in the established U.S. market.
Is succimer a good target for pharmaceutical licensing?
Succimer alone is generally a limited licensing asset. Its strategic value is greater when combined with antidotes, hospital generics, government procurement rights, or an established emergency-medicine distribution platform.
References
-
U.S. Food and Drug Administration. (n.d.). Chemet (succimer) prescribing information. FDA.
-
Centers for Disease Control and Prevention. (2022). Blood lead levels in children aged 1-5 years: National Health and Nutrition Examination Survey. CDC.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Agency for Toxic Substances and Disease Registry. (2020). Toxicological profile for lead. U.S. Department of Health and Human Services.
-
World Health Organization. (2021). WHO guideline for clinical management of exposure to lead. World Health Organization.
